10:53 AM EDT, 07/11/2025 (MT Newswires) -- MiNK Therapeutics ( INKT ) said Friday that a patient with metastatic, treatment-resistant testicular cancer achieved "complete and durable remission" following treatment with its investigational invariant natural killer, or iNKT, cell therapy.

The company said the case involving a patient who was given a single infusion of MiNK's agenT-797 with nivolumab after previous treatments failed was published on Nature's Oncogene.

The patient achieved remission, with no evidence of disease over two years later, MiNK said.

Donor iNKT cells were detectable for up to six months after infusion and the treatment was well-tolerated with no serious side effects, the company said.

Shares of MiNK were up more than 638% in recent Friday trading.

Price: 57.09, Change: +49.36, Percent Change: +638.53